

TECHNICAL PROBLEMS UNDERLYING THE PRESENT INVENTION


As explained above, there existed a need in the prior art for effective therapies for the treatment of neutrophilic dermatoses, such as Hidradenitis suppurativa (HS), and cutaneous neutrophilic autoimmune diseases.

5 The present inventors have now surprisingly found that molecules inhibiting C5a signaling, e.g. an anti-C5a antibody, are exceptionally well-suited for the treatment of Hidradenitis suppurativa. The present inventors have additionally studied the physiological mechanism leading to neutrophil activation and found out that C5a is the key driver of neutrophil activation.

10 Thus, the present inventors expect that inhibiting C5a activity will be a suitable therapy approach for the treatment of various neutrophilic disorders, especially cutaneous, neutrophilic, inflammatory diseases.

SUMMARY

15 In one aspect the present disclosure refers to the use of a compound in the manufacture of a medicament for treating a cutaneous, neutrophilic, inflammatory disease in a subject, wherein the compound is an inhibitor of C5a activity, and wherein the cutaneous, neutrophilic, inflammatory disease is selected from the group consisting of hidradenitis suppurativa (HS); PASH (PG, acne and hidradenitis suppurativa); PAPASH (pyogenic arthritis, acne, PG and hidradenitis suppurativa), wherein the inhibitor of C5a activity directly binds to a C5a receptor and inhibits the activity of the
20 C5a, wherein the inhibitor of C5a activity has a structure according to formula (I):



25 In one example, there is disclosed a method for the treatment of a cutaneous, neutrophilic, inflammatory disease in a subject, comprising the step of: administering to a subject in need thereof a therapeutic amount of a compound, wherein the compound is an inhibitor of C5a activity, and wherein the cutaneous, neutrophilic, inflammatory disease is selected from the group consisting of hidradenitis suppurativa (HS); Pyoderma gangrenosum (PG); PAPA (pyogenic arthritis, PG and acne); PASH (PG, acne and hidradenitis suppurativa); PAPASH (pyogenic arthritis, acne, PG and hidradenitis suppurativa); Sweet syndrome (SS); subcorneal pustular dermatosis (SPD); epidermolysis bullosa acquisita,

CLAIMS

1. Use of a compound in the manufacture of a medicament for treating a cutaneous, neutrophilic, inflammatory disease in a subject, wherein the compound is an inhibitor of C5a activity, and
5 wherein the cutaneous, neutrophilic, inflammatory disease is selected from the group consisting of hidradenitis suppurativa (HS); PASH (PG, acne and hidradenitis suppurativa); PAPASH (pyogenic arthritis, acne, PG and hidradenitis suppurativa), wherein the inhibitor of C5a activity has a structure according to formula (I):

